Pulse Biosciences to Report First Quarter 2018 Financial Results and Operational Highlights
April 30 2018 - 4:01PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology
company developing a proprietary therapeutic tissue treatment based
on its Nano-Pulse Stimulation (NPS) platform, today announced that
the Company will report first quarter 2018 financial results and
operational highlights on Tuesday, May 8, 2018. Pulse Biosciences
management will host a conference call and webcast at 4:30 p.m.
Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by
dialing (844) 494-0190 (domestic) and (508) 637-5580
(international) using the conference ID# 4796365. The webcast of
the conference call can be accessed live on the Investor Relations
section of the Pulse Biosciences website at
www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a clinical stage electroceutical, an
electrical energy based therapeutic, company pursuing commercial
applications of its proprietary Nano-Pulse Stimulation (NPS)
technology. NPS is a non-thermal, precise, focal, drug-free tissue
treatment technology utilizing nanosecond (billionth of a second)
range pulsed electric fields that directly affect the cell membrane
and intracellular structures and initiates programmed cell death in
treated cells. The unique ability of NPS to initiate cell death has
the potential to significantly benefit patients in a wide variety
of medical applications including applications in immuno-oncology
and dermatology, and other potential applications we may pursue in
the future. The initiation of programmed cell death by NPS results
in a minimal inflammatory response, which improves healing outcomes
and supports the replacement of treated tissue cells with healthy
tissue cells. In cancerous lesions, NPS has been shown in
preclinical models to induce immunogenic cell death (ICD), which
exposes the unique antigens of the treated cells to the immune
system and enrolls immune system cells, such as cytotoxic T-cells
to mount an adaptive immune response. Pulse Biosciences is
investigating a variety of applications for its technology that
exploits the technology’s unique biologic effect, including
immuno-oncology and dermatology. More information is available at
www.pulsebiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180430006386/en/
Investor Relations:Pulse Biosciences, Inc.Brian DowSr.
Vice President and Chief Financial
OfficerIR@pulsebiosciences.comorSolebury TroutBill
Kadel646-378-2934Bkadel@Troutgroup.comorMedia:Sam Brown,
Inc.Christy Curran615-414-8668christycurran@sambrown.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024